Asprosin contributes to nonalcoholic fatty liver disease through regulating lipid accumulation and inflammatory response via AMPK signaling

被引:7
|
作者
Zhang, Bo [1 ,4 ]
Lu, Jinger [2 ]
Jiang, Yuhua [1 ]
Feng, Yan [3 ]
机构
[1] Ningbo Univ, Affiliated Peoples Hosp, Dept Infect Dis, Ningbo, Zhejiang, Peoples R China
[2] Ningbo Univ, Affiliated Peoples Hosp, Dept Endocrine, Ningbo, Zhejiang, Peoples R China
[3] 75th Grp Army Hosp PLA, Dept Digest Blood Endocrinol, Dali, Yunnan, Peoples R China
[4] Ningbo Univ, Affiliated Peoples Hosp, 251 Baizhang East Rd, Ningbo 315040, Zhejiang, Peoples R China
关键词
AMPK signaling; Asprosin; inflammatory response; lipid accumulation; nonalcoholic fatty liver disease; PATHOGENESIS;
D O I
10.1002/iid3.947
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundNonalcoholic fatty liver disease (NAFLD) is a primary contributor to liver-related morbidity and mortality. Asprosin has been reported to be implicated in NAFLD. AimsThis work is to illuminate the effects of Asprosin on NAFLD and the possible downstream mechanism. Materials & MethodsThe weight of NAFLD mice induced by a high-fat diet was detected. Quantitative reverse-transcription polymerase chain reaction (RT-qPCR) examined serum Asprosin expression. RT-qPCR and western blot analysis examined Asprosin expression in mice liver tissues. Intraperitoneal glucose tolerance test (IPGTT) and intraperitoneal insulin tolerance test (IPITT) were implemented. Biochemical kits tested liver enzyme levels in mice serum and liver tissues. Hematoxylin and eosin staining evaluated liver histology. Liver weight was also tested and oil red O staining estimated lipid accumulation. RT-qPCR and western blot analysis analyzed the expression of gluconeogenesis-, fatty acid biosynthesis-, fatty acid oxidation-, and inflammation-associated factors. Besides, western blot analysis examined the expression of AMP-activated protein kinase (AMPK)/p38 signaling-associated factors. In palmitic acid (PA)-treated mice hepatocytes, RT-qPCR and western blot analysis examined Asprosin expression. Lipid accumulation, gluconeogenesis, fatty acid biosynthesis, fatty acid oxidation, and inflammation were appraised again. ResultsAsprosin was overexpressed in the serum and liver tissues of NAFLD mice and PA-treated mice hepatocytes. Asprosin interference reduced mice body and liver weight, improved glucose tolerance and diminished liver injury in vivo. Asprosin knockdown alleviated lipid accumulation and inflammatory infiltration both in vitro and in vivo. Additionally, Asprosin absence activated AMPK/p38 signaling and AMPK inhibitor Compound C reversed the impacts of Asprosin on lipid accumulation and inflammatory response. ConclusionCollectively, Asprosin inhibition suppressed lipid accumulation and inflammation to obstruct NAFLD through AMPK/p38 signaling.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] SGL 121 Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism Through AMPK Signaling Pathway
    Kim, Da Eun
    Chang, Bo Yoon
    Jeon, Byeong Min
    Baek, Jong In
    Kim, Sun Chang
    Kim, Sung Yeon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) : 1 - 16
  • [2] Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway
    Yu, Peng
    Xu, Xi
    Zhang, Jing
    Xia, Xuan
    Xu, Fen
    Weng, Jianping
    Lai, Xiaoyang
    Shen, Yunfeng
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2019, 2019
  • [3] Shugan Jiangzhi Decoction Alleviates Nonalcoholic Fatty Liver Disease (NAFLD) via Regulating AMPK/PPAR Signaling Pathway
    Chen, Lijuan
    Li, Wen
    Fu, Yanli
    Lei, Yuhe
    Xie, Wenjian
    Rong, Suihua
    Li, Ning
    Zhang, Miaomiao
    He, Jiayi
    Chen, Yanfen
    Wu, Dinghong
    LETTERS IN DRUG DESIGN & DISCOVERY, 2024, 21 (13) : 2740 - 2750
  • [4] Therapeutic efficacy of polydatin for nonalcoholic fatty liver disease via regulating inflammatory response in obese mice
    Mo, Juan-Fen
    Wu, Jia-Yuan
    Zheng, Li
    Yu, Ya-Wei
    Zhang, Tian-Xin
    Guo, Li
    Bao, Yi
    RSC ADVANCES, 2018, 8 (54) : 31194 - 31200
  • [5] Therapeutic efficacy of polydatin for nonalcoholic fatty liver disease via regulating inflammatory response in obese mice
    Mo J.-F.
    Wu J.-Y.
    Zheng L.
    Yu Y.-W.
    Zhang T.-X.
    Guo L.
    Bao Y.
    Bao, Yi (baoyi@jxey.com), 2018, Royal Society of Chemistry (08) : 31194 - 31200
  • [6] Spermidine ameliorates non-alcoholic fatty liver disease through regulating lipid metabolism via AMPK
    Gao, Mingyue
    Zhao, Wei
    Li, Chunmei
    Xie, Xianghong
    Li, Meixia
    Bi, Yalan
    Fang, Fude
    Du, Yunfeng
    Liu, Xiaojun
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 505 (01) : 93 - 98
  • [7] Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-κB signaling pathways
    Li, Chun-Xiao
    Gao, Jian-Guo
    Wan, Xing-Yong
    Chen, Yi
    Xu, Cheng-Fu
    Feng, Ze-Min
    Zeng, Hang
    Lin, Yi-Ming
    Ma, Han
    Xu, Ping
    Yu, Chao-Hui
    Li, You-Ming
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (34) : 5120 - 5133
  • [8] Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-κB signaling pathways
    Chun-Xiao Li
    Jian-Guo Gao
    Xing-Yong Wan
    Yi Chen
    Cheng-Fu Xu
    Ze-Min Feng
    Hang Zeng
    Yi-Ming Lin
    Han Ma
    Ping Xu
    Chao-Hui Yu
    You-Ming Li
    World Journal of Gastroenterology, 2019, (34) : 5120 - 5133
  • [9] Asprosin aggravates nonalcoholic fatty liver disease via inflammation and lipid metabolic disturbance mediated by reactive oxygen species
    Wang, Chaowen
    Zeng, Wenjing
    Wang, Li
    Xiong, Xiaowei
    Chen, Sheng
    Huang, Qianqian
    Zeng, Guohua
    Huang, Qiren
    DRUG DEVELOPMENT RESEARCH, 2024, 85 (04)
  • [10] Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro
    Wei, Dan
    Wu, Shaofei
    Liu, Jie
    Zhang, Xiaoqian
    Guan, Xiaoling
    Gao, Li
    Xu, Zhipeng
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2021, 99 (08) : 775 - 785